中国China Patent OfficeCNIPAFeePCT
2024年9月6日

New Fee Standards Released for Chinese Patent Applications

by
刘勇博士
王怡瑾女士

Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE).

Please find our summary below:

PCT application fee deduction rules

 

Application fee & extra fees (claims/pages)

Substantive examination fee

PCT application type

Before

Jul 26, 20242

After

Jul 26, 2024

Before

Jul 26, 2024

After

Jul 26, 2024

CNIPAas RO

CNIPA as ISA or IPEA

100% OFF

100% OFF

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

100% OFF

No discount

20% OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

non-CN as RO

CNIPA as ISA or IPEA

No discount

No discount

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

No discount

No discount

20%OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

  • Abbreviations

    • CNIPA - China National Intellectual Property Administration

    • Non-CN – other patent offices than CNIPA

    • NPE - National Phase Entry

    • IPEA - International Preliminary Examining Authority
  • RO - Receiving Office

  • ISA - International Search Authority

  • EPO - European Patent Office

  • JPO - Japan Patent Office

  • SPO - Swedish Patent Office

Fee standards for PTA/PTE

Under the new fee schedule, the official fee for PTA/PTE requests is CNY 200/patent. If any PTA/PTE request has been filed before July 26, 2024, the PTA/PTE request fee thereof must be paid before October 26, 2024.

If PTA/PTE is granted, the annuity fee during the patent compensation period is CNY 8000/patent/year.

A SPECIAL NOTE: The annuity fee for the patent compensation period must be paid in a lump sum before the expiration of the 20-year patent term. No late payment, restoration, or fee reduction is applicable.

Others

During the implementation period of the patent open license, the annuity fee will be reduced by 15%. If other patent fee reduction policies are also applicable, the most favorable policy can be selected, but only one fee reduction policy may be used per patent.

EIP Thoughts

The new PCT application fee deduction rules are intended to promote CNIPA as the ISA and IPEA for international patent applications.

It has been over four years since PTA/PTE were first introduced in the latest 4th Amendment to the Patent Law. Now we finally have a complete set of procedural requirements for PTA/PTE requests. So far, the procedure has been smooth, and we have already had several requests successfully granted.

We will continue to monitor developments closely and keep you informed of any further updates.

Related Articles

A More Detailed Overview of China’s Patent Term Extension (PTE) System

Everything you need to know about Patent Term Adjustment (PTA) in China

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

    1. Notice on Adjusting and Optimizing Patent Fee Policy, Finance and Taxation [2024] No. 23” and “Notice on the Annual Fee Standard for the Patent Compensation Period and Other Related Matters, Development and Reform Price [2024] No. 1156,” and “Announcement on Adjusting Certain Patent Fee Standards and Reduction Policies (No. 594)” and “Notice on the Payment of Patent Term Compensation Fees and Other Related Matters”.

      ↩︎
    2. Appendix 2 of “Notice of the National Development and Reform Commission and the Ministry of Finance on Reissuing the Administrative and Institutional Fee Standards of the National Intellectual Property Administration and Other Related Issues, Development and Reform Price [2017] No. 270.”

      ↩︎

    其他文章

    RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

    2025年3月10日
    An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

    CHINA: New Patent Examination Guidelines Now Available for Public Comment

    2021年8月4日
    Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]

    China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

    2021年4月29日
    This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

    China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

    2022年9月21日
    China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

    我们的过去活动

    Top crossarrow-right